Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pancreatic cancer
Biotech
ESMO: Incyte claims ‘neck and neck’ KRAS G12D race with RevMed
Incyte has unveiled phase 1 data suggesting its KRAS G12D inhibitor could rival RevMed’s contender in the increasingly competitive pancreatic cancer space.
James Waldron
Oct 26, 2026 9:45am
Tango trims headcount after showcasing RevMed combo's potential
Oct 26, 2026 5:06am
Verastem CEO says RAS drug 'set new benchmark' for tricky cancer
Oct 14, 2026 10:27am
The future of RAS inhibitors
Sep 11, 2026 9:48am
Fierce Pharma
FDA greenlights RevMed’s pancreatic cancer gamechanger
Aug 26, 2026 11:30am
Craif raises $33M to boost work on its urine test for cancer
Aug 18, 2026 10:04am